The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis

Claus Madsen*

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

323 Downloads (Pure)

Abstract

The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.

Original languageEnglish
Article numbere00696
JournalBrain and Behavior
Volume7
Issue number6
Number of pages8
ISSN2162-3279
DOIs
Publication statusPublished - 2017

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Pharmacokinetics

Keywords

  • interferon beta
  • multiple sclerosis
  • peginterferon beta-1a
  • RRMS

Cite this

@article{e82655c7e0cb4711b1b300a3e2f1d530,
title = "The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis",
abstract = "The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.",
keywords = "interferon beta, multiple sclerosis, peginterferon beta-1a, RRMS",
author = "Claus Madsen",
year = "2017",
doi = "10.1002/brb3.696",
language = "English",
volume = "7",
journal = "Brain and Behavior",
issn = "2162-3279",
publisher = "JohnWiley & Sons Ltd.",
number = "6",

}

The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. / Madsen, Claus.

In: Brain and Behavior, Vol. 7, No. 6, e00696, 2017.

Research output: Contribution to journalReviewResearchpeer-review

TY - JOUR

T1 - The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis

AU - Madsen, Claus

PY - 2017

Y1 - 2017

N2 - The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.

AB - The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.

KW - interferon beta

KW - multiple sclerosis

KW - peginterferon beta-1a

KW - RRMS

U2 - 10.1002/brb3.696

DO - 10.1002/brb3.696

M3 - Review

C2 - 28638705

AN - SCOPUS:85019035665

VL - 7

JO - Brain and Behavior

JF - Brain and Behavior

SN - 2162-3279

IS - 6

M1 - e00696

ER -